This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Adam Feuerstein

Senior Columnist

Before joining TheStreet in March 2001, Feuerstein covered business software for Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.

Feuerstein graduated from Emory University with a bachelor's degree in political science.

Adam Feuerstein
By This Author:
Page 2 of 582

Roche to Acquire Majority Stake in Cancer Genetic Test Maker Foundation Medicine

By Adam Feuerstein

Roche's $1 billion-plus investment in Foundation Medicine aims to expand use of genetic testing to develop new, more effective drugs.

01:00AM 01/12/15

Tale of 2 Rare Disease Stocks: Aegerion, NPS Pharmaceuticals

By Adam Feuerstein

A successful rare-disease drug launch and the development of a second product made NPS an attractive takeout target.

12:15AM 01/12/15

Gilead, Express Scripts May Be Movers Next Week Amid Healthcare Conference

By Adam Feuerstein

TheStreet senior columnist Adam Feuerstein previews what to watch at the J.P. Morgan Healthcare Conference, which kicks off Monday in San Francisco.

03:11PM 01/09/15

'Free the Webcast!' Investor Transparency Gains Momentum at 'JPM15' Healthcare Confab

By Adam Feuerstein

Following a week of awareness raising through phone calls, Twitter and a Loncar guest appearance on CNBC, the number of JPM breakout session webcasts has increased significantly.

02:56PM 01/09/15

Biotech Investors' Guide and Preview to J.P. Morgan Healthcare Conference: Part 2

By Adam Feuerstein

The much ballyhooed J.P. Morgan Healthcare Conference kicks off Monday in San Francisco. Here are capsule summaries of some of the expected story lines from presenting companies.

07:40AM 01/09/15

Biotech Investors Guide and Preview to the J.P. Morgan Healthcare Conference Part 1

By Adam Feuerstein

The much ballyhooed J.P. Morgan Healthcare Conference kicks off Monday in San Francisco. Here are capsule summaries of some of the expected story lines from presenting companies.

01:09PM 01/08/15

Biogen's Nerve Repair Drug Yields Mixed Results in Key Eye Trial

By Adam Feuerstein

Anti-LINGO-1 is Biogen's most important pipeline drug candidate.

08:34AM 01/08/15

Biogen Idec's Critical Nerve Repair Drug is Poised for Big News -- Soon

By Adam Feuerstein

Study results from the most important drug in Biogen Idec's pipeline are expected as early as Monday. Here are essential points you need to know.

06:15AM 01/08/15

Alkermes CEO: Our Proprietary Drug Pipeline Is 'Maturing Beautifully'

By Adam Feuerstein

With two positive data releases in consecutive days this week, Alkermes is enjoying a strong start to the year.

10:49AM 01/07/15

Public Shame for Biotechs Not Webcasting 'JPM15' Breakout Sessions

By Adam Feuerstein

In a blow to investor transparency, an embarrassingly small number of healthcare companies are webcasting their Q&A breakout sessions at next week's J.P. Morgan Healthcare Conference.

03:08PM 01/06/15

Page 2 of 582

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV


DOW 17,672.60 -141.38 -0.79%
S&P 500 2,051.82 -11.33 -0.55%
NASDAQ 4,757.8790 +7.4820 0.16%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs